COMBINATION THERAPIES OR STANDALONE INTERVENTIONS? INNOVATION OPTIONS FOR PHARMACEUTICAL FIRMS FIGHTING CANCER

Gunjan Bhardwaj (), Anshit Agrawal () and Rupesh Tyagi ()
Additional contact information
Gunjan Bhardwaj: European Business School, Gustav-Stresemann-Ring 3, 65189 Wiesbaden, Germany
Anshit Agrawal: Innoplexus, India, MG Road, Gurgaon, Haryana, 122002, India
Rupesh Tyagi: Innoplexus, India, MG Road, Gurgaon, Haryana, 122002, India

International Journal of Innovation Management (ijim), 2015, vol. 19, issue 03, 1-16

Abstract: Innovation is key to the pharma model, from an initial discovery to the final development of a marketable drug. Here, we explore the innovation options in the fiercely contested therapeutic area of Oncology. We studied clinical development of drugs targeting PD-1 and PD-L1 pathway. In this interesting contest, companies seem to be focusing on standalone interventions (exploratory innovation) and combination therapy (exploitative innovation) in clinical development. Merck Sharp and Dohme, having a relatively weaker oncology pipeline seems to take exploratory approach of standalone intervention. However for some indications, MSD seems to harness exploitative innovation approach through combination therapies by collaborating with external partners. AstraZeneca in contrast seems to focus on exploitative approach using its strong oncology pipeline for combination therapies. Our work provides a framework to understand exploratory (standalone) and exploitative (combination therapy) innovation approaches and their relationship to capability, scientific networks and market access for a company entering a fiercely contested pharmaceutical market.

Keywords: Exploratory approach; exploitative approach; standalone; combination therapies; oncology; PD-1/PD-L1; network ecosystem (search for similar items in EconPapers)
Date: 2015
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.worldscientific.com/doi/abs/10.1142/S1363919615400034
Access to full text is restricted to subscribers

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wsi:ijimxx:v:19:y:2015:i:03:n:s1363919615400034

Ordering information: This journal article can be ordered from

DOI: 10.1142/S1363919615400034

Access Statistics for this article

International Journal of Innovation Management (ijim) is currently edited by Joe Tidd

More articles in International Journal of Innovation Management (ijim) from World Scientific Publishing Co. Pte. Ltd.
Bibliographic data for series maintained by Tai Tone Lim ().